Clinical Trial Update: Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma [NA]

View source ↗

Summary

An Imperial College London-sponsored clinical trial evaluating individualized dosimetry for Holmium-166 radioembolization in unresectable hepatocellular carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• QuiremSpheres (Holmium-166 microspheres)

Snippet

Sponsor: Imperial College London | Conditions: Carcinoma, Hepatocellular | NA | Status: TERMINATED